Pharma in her DNA, Wockhardt scion ready for deep dive in the US

Zahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacterial infections and is a significant bet for the company. Zaynich's US approval marks a major breakthrough after decades without new antibiotics. Zahabiya is focused on hospital penetration, physician advocacy, and demonstrating economic value to healthcare systems.

Raccontata daeconomictimes.indiatimes.com